Not finding it? Sign in to also search OpenAlex live.
-
Sensitive detection of minimal residual disease and immunotherapy targets by multi-modal bone marrow analysis in high-risk neuroblastoma – a multi-center study2025 Journal of Experimental & Clinical Cancer Research article Medicine Neuroblastoma Research and Treatments Open access
Nina U. Gelineau, Eva Bozsaky, Lieke M. J. van Zogchel, Fikret Rifatbegovic, Daria Lazic, Andrea M. Ziegler, +12 more
5citations -
Validation of minimal risk of recurrence classification by the Breast Cancer Index in early stage breast cancer2025 npj Breast Cancer article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
Marie-France Jilderda, John M.S. Bartlett, Gerrit‐Jan Liefers, Y Zhang, Hywel Dunn-Davies, Valerie Rebattu, +12 more
2citations -
Identification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index2025 Clinical Cancer Research article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
Marie-France Jilderda, Yi Zhang, Valerie Rebattu, Ranelle C. Salunga, Wilma E. Mesker, Jenna Wong, +8 more
3citations -
Predictive Added Value of Selected Plasma Lipids to a Re-estimated Minimal Risk Tool2021 Frontiers in Cardiovascular Medicine article Medicine Lipoproteins and Cardiovascular Health Open access
Antonella Bodini, Elena Michelucci, Nicoletta Di Giorgi, Chiara Caselli, Giovanni Signore, Danilo Neglia, +6 more
5citations -
Minimal Residual Disease Detection in Peripheral Blood of Patients With High-Risk Neuroblastoma Correlates With Outcome in the International GPOH-DCOG Prospective Validation Study
Nina U. Gelineau, Lieke M. J. van Zogchel, B. De Carolis, Esther M. van Wezel, Lily Zappeij‐Kannegieter, Ahmad Javadi, +9 more
1citations -
High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time: Results from the ATALANTA-1 MCL cohort
Marie José Kersten, Joost S.P. Vermaat, Pim G. N. J. Mutsaers, Maria Theresa Kuipers, Évelyne Willems, Sébastien Anguille, +14 more
3citations -
PCV38 Predictive Added Value of Selected Plasma Lipids to an Updated Minimal Risk Tool2021 Value in Health conference-abstract Medicine Lipoproteins and Cardiovascular Health Open access
Antonella Bodini, Elena Michelucci, Chiara Caselli, Giovanni Signore, Danilo Neglia, Jeff M. Smit, +5 more
0citations -
367P Validation of minimal risk of recurrence classification by the breast cancer index2025 Annals of Oncology article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
M-F. Jilderda, JMS Bartlett, Gerrit‐Jan Liefers, Yi Zhang, Hywel Dunn-Davies, Valerie Rebattu, +12 more
0citations -
Added value of tumor–stroma ratio to postsurgery circulating tumor DNA and pTN stage in risk stratification of patients with stage III colon cancer treated with adjuvant chemotherapy
Ingrid A. Franken, F. Heilijgers, M.-C.E. Bakker, Carmen Rubio Alarcon, Frederieke H. van der Baan, Margriet Lemmens, +8 more
3citations -
Improved Outcome for ALL by Prolonging Therapy for IKZF1 Deletion and Decreasing Therapy for Other Risk Groups2023 Journal of Clinical Oncology article Medicine Acute Lymphoblastic Leukemia research Open access
Rob Pieters, Hester de Groot‐Kruseman, Marta F. Fiocco, Femke Verwer, Merian van Overveld, Edwin Sonneveld, +11 more
42citations -
Sensitive liquid biopsy monitoring correlates with outcome in the prospective international GPOH-DCOG high-risk neuroblastoma RT-qPCR validation study2024 Journal of Experimental & Clinical Cancer Research article Medicine Neuroblastoma Research and Treatments Open access
Lieke M. J. van Zogchel, Boris Decarolis, Esther M. van Wezel, Lily Zappeij‐Kannegieter, Nina U. Gelineau, Roswitha Schumacher‐Kuckelkorn, +8 more
5citations -
Patient‐reported outcomes: active surveillance vs radical therapies in low‐risk prostate cancer2026 British Journal of Urology article Medicine Prostate Cancer Diagnosis and Treatment Open access
Mulham Al‐Nader, Claudia Kesch, Osama Mahmoud, Boris Alexander Hadaschik, Jan Fichtner, G Carl, +38 more
0citations -
MM-329 Daratumumab + Bortezomib/Lenalidomide/Dexamethasone (D-VRd) in Transplant-Eligible (TE) Patients With Newly Diagnosed Myeloma (NDMM): Analysis of the Phase 3 PERSEUS Study Based on High-Risk Cytogenetic Abnormalities (HRCAs)2024 Clinical Lymphoma Myeloma & Leukemia conference-abstract Medicine Multiple Myeloma Research and Treatments
Meletios Athanasios Dimopoulos, Pieter Sonneveld, Paula Rodríguez‐Otero, Hang Quach, P. Joy Ho, Meral Beksaç, +33 more
3citations -
Prophylactic Donor Lymphocyte Infusion in Patients after Allogeneic Stem Cell Transplantation with Post-Transplant Cyclophosphamide Is Associated with Low Relapse Risk and Excellent Survival in Patients below 65 Years with Acute Myeloid Leukemia and High-Risk Myelodysplasia
Peter A. von dem Borne, Tjeerd J.F. Snijders, Daniëlle van Lammeren, Janneke Tijmensen, Erwin V. Planken, Henriëtte Levenga, +9 more
1citations